Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody

A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

(2017) M. N. Saleh et al.   JOURNAL OF CLINICAL ONCOLOGY

Guide to Receptors and Channels (GRAC), 5th edition

(2011) SPH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf

(2011) Kuen-Feng Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma

(2011) Wei-Tien Tai et al.   JOURNAL OF HEPATOLOGY

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Death Receptor Agonists as a Targeted Therapy for Cancer

(2010) J. Wiezorek et al.   CLINICAL CANCER RESEARCH

Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3

(2010) K.-F. Chen et al.   CLINICAL CANCER RESEARCH

Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects

(2010) W. Zhang et al.   CLINICAL CANCER RESEARCH

The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms

(2010) D. Llobet et al.   EUROPEAN JOURNAL OF CANCER

Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells

(2010) S. Huang et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2

(2009) Boris R. A. Blechacz et al.   HEPATOLOGY

Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway

(2009) Kuen-Feng Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Boswellic Acid Blocks Signal Transducers and Activators of Transcription 3 Signaling, Proliferation, and Survival of Multiple Myeloma via the Protein Tyrosine Phosphatase SHP-1

(2009) Ajaikumar B. Kunnumakkara et al.   MOLECULAR CANCER RESEARCH

TRAIL-induced apoptosis of hepatocellular carcinoma cells isaugmented by targeted therapies

(2009) Bruno Christian Koehler et al.   WORLD JOURNAL OF GASTROENTEROLOGY

A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes

(2008) A. Yada et al.   ANNALS OF ONCOLOGY

Mcl-1: A Gateway to TRAIL Sensitization

(2008) S.-H. Kim et al.   CANCER RESEARCH

Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells

(2008) K.-F. Chen et al.   CANCER RESEARCH

Molecularly targeted therapy for hepatocellular carcinoma

(2008) Shinji Tanaka et al.   CANCER SCIENCE

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas

(2008) F. Yang et al.   MOLECULAR CANCER THERAPEUTICS

Butein Suppresses Constitutive and Inducible Signal Transducer and Activator of Transcription (STAT) 3 Activation and STAT3-Regulated Gene Products through the Induction of a Protein Tyrosine Phosphatase SHP-1

(2008) M. K. Pandey et al.   MOLECULAR PHARMACOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway

(2008) S Wang   ONCOGENE